We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Adipose-Derived Stem Cells Show Promise in Breast Reconstruction

By HospiMedica staff writers
Posted on 04 Feb 2008
Adipose derived stem and progenitor cells (ADRCs) recovered from fat tissue are being used in reconstructive breast surgery, helping to restore lost breast volume and contour. More...


Researchers from Kyushu Central Hospital (Fukuoka, Japan) conducted an independent, investigator-sponsored study evaluation of a total of 21 women aged from 29 to 59 (mean 46.9) years who underwent 25 stem cell augmented reconstructions at the department of breast surgery. All patients had no metastases or recurrence at least one year after tissue loss resulting from partial mastectomy. Under general anesthesia, adipose tissue (approximately twice the estimated volume to be used for reconstruction) was harvested by lipoaspiration using standard tumescent technique. Half of the fat was reserved to extract, wash, and concentrate the ADRCs; the other half was used as the primary filler material. This tissue, which was fragmented into numerous 2 to 5 mm fragments by the lipoaspiration procedure, was then enriched with concentrated ADRCs, made available at the time of surgery via an investigational device, the Celution System, under development by Cytori Therapeutics (San Diego, CA, USA). Tissue thickness measurement (TTM) was performed using an ultrasound machine at 3 and 6 months post-procedure.

Study results showed a statistically significant improvement in average breast tissue thickness at one month following treatment compared to baseline, with no significant loss of tissue thickness between one month and the final assessment. The procedure was reported safe and well tolerated in all women; no rejection or immune response was observed; patient satisfaction of the outcome was reported at 79%, with a mean follow up period of 7.7 months. The study results were presented at the 30th San Antonio Breast Cancer Symposium, held during December 2007 in Texas (USA).

"Reconstructive options have not kept pace with the development of new cancer therapies and existing reconstructive options for women are either ineffective, impractical or both,” said Marc H. Hedrick, M.D., president of Cytori Therapeutics. "Until now, partial mastectomy patients have had little hope other than to live with tissue loss. This procedure holds the potential to offer women the opportunity to restore the contour, volume and function lost during cancer treatment.”

More than one million women worldwide are diagnosed with breast cancer annually, including more than 370,000 women in Europe and more than 210,000 in the United States. Due to continual advancements in cancer detection, a growing percentage of women are eligible for partial mastectomies. Unfortunately, partial mastectomy often results in significant skin damage, tissue loss, pain, and reduction or loss of motion. Women who undergo such procedures have limited reconstructive options to potentially reduce associated pain, reverse loss of motion, and restore breast volume and contour.


Related Links:
Kyushu Central Hospital
Cytori Therapeutics

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.